SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination

SciSparc Ltd. (SPRC) — TEL AVIV, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced that the Japanese Patent Office has granted the company a patent for NeuroThera’s pharmacological combination titled “Compositions and Methods for Potentiating Derivatives of 4-Aminophenols.” Th

Source: GlobeNewswire — read the full announcement there.

See our SciSparc company profile for background, links, and more SciSparc news.